$AME

AMETEK (AME) Raises Full Year Guidance, Is The Stock Still Cheap?

AMETEK (AME) reported higher Q2 sales and net income year over year, raised full-year guidance, and reaffirmed its regular quarterly dividend, according to the company. The stock trades at $253.66. A fair-value narrative cites about $265.33 and a 39.4x forward P/E versus 36.9x currently.

Original reporting
Published Aug 9, 2026, 6:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 9, 2026, 7:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AMETEK (AME) Raises Full Year Guidance, Is The Stock Still Cheap? — source image
Decision brief

The 30-second read

$AMEBullishMed
01

Why it matters

The actionable takeaway is whether the market has already priced the guidance upgrade, given the article’s emphasis on a rich earnings multiple versus a lower implied fair P/E and a lower DCF cash-flow value.

02

Market read

AMETEK’s guidance raise and dividend support near-term sentiment, but the article highlights valuation compression risk if execution or end-market conditions soften.

03

What to watch

The piece does not quantify the guidance magnitude, margin drivers, or acquisition/integration progress, which are key to whether the upgrade is durable.

Relevance 6/10Novelty 5/10Timing: after-hours or same-day read-through following the Q2 results and full-year guidance raise

Background

Simply Wall St frames AMETEK’s Q2 beat and guidance raise as a valuation question, comparing a “fair value” view to a DCF output.

Company-level read

Ticker impact

$AMEBullishMedium confidence
Context

AMETEK reported higher Q2 sales and net income, raised full-year guidance, and affirmed its regular quarterly dividend.

Expected impact

Likely supports upward bias in the near term, with volatility risk if investors view the upgrade as already priced.

Evidence & confidence

The text provides a guidance-upgrade and dividend confirmation as the core catalysts, but it also highlights a valuation gap versus a lower “fair” P/E and a DCF implying downside.

Market effects

Signals continued demand and execution in industrials/electromechanical end markets, but the article does not provide sector-wide data.

No specific regional macro or demand details beyond US-listed price performance.

No explicit global supply chain or international regulatory developments mentioned.

Counterpoint

The article’s DCF estimate is materially below the current price, implying the guidance raise may not justify the valuation if end-market strength fades.

Key entities

  • AMETEK

    US-listed industrial company whose Q2 results, full-year guidance, and dividend affirmation are cited as the catalysts.

Related articles

$AMEHighAI 9/10

AMETEK Completes Acquisition of Indicor Instrumentation

AMETEK, Inc. (NYSE: AME) completed its $5.0 billion acquisition of Indicor Instrumentation. The deal adds businesses that design and manufacture mission-critical industrial and scientific solutions. Indicor Instrumentation is expected to contribute $350 million to AMETEK's 2026 sales and be modestly accretive to earnings. The acquisition aligns with AMETEK's growth strategies and market focus.

$AMEHighAI 9/10

AMETEK Raises 2026 Outlook After Earnings Climb 17%

AMETEK (NYSE: AME) raised its 2026 outlook after Q2 results. Second-quarter adjusted earnings rose 17% to $2.09 per diluted share, with sales up 15% to $2.04 billion and orders up 28%. AMETEK now expects 2026 adjusted earnings of $8.20 to $8.30 per share and sales up about 10% from 2025.

$AMEHighAI 9/10

AMETEK (AME) Q2 2026 Earnings Call Transcript

AMETEK (AME) reported Q2 2026 net sales of $2.04B, up 15% year over year, with 10% organic growth. Adjusted EPS was $2.09, up 17%, above guidance of $1.96 to $2.00. Total orders were $2.3B, up 28%, backlog $4.11B. Full-year sales guidance rose about 10% and adjusted EPS to $8.20-$8.30.

$AMEMed

Segment Demand and Strategic Acquisitions Propel Growth

AMETEK (NYSE: AME) reported Q2 CY2026 revenue of $2.04 billion, up 15% year over year, beating Wall Street expectations. Non-GAAP EPS was $2.09, 4.8% above consensus. Management cited organic growth, rising orders and backlog of $4.11 billion, and contributions from acquisitions. Full-year guidance was raised, supported by AI, defense, and power grid demand.

$AMEMedAI 8/10

AMETEK, Inc. Q2 2026 Earnings Call Summary

AMETEK reported Q2 2026 momentum driven by multi-year infrastructure build-outs for AI, semiconductors, and power. Organic sales growth accelerated, with a record $4.11B backlog and about 80% expected to ship in 12 months. Core EMG margins rose 290 bps. Full-year 2026 organic sales guidance was raised to mid-to-high single digits; Indicor Instrumentation acquisition of $5B expected to close in H2 with 10% to 12% synergies.

$AMEHigh

AMETEK INC/ (AME): Results of Operations and Financial Condition

AMETEK INC/ (AME) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ametek8kexhibit99108042026.htm EX-99.1 Document Exhibit 99.1 AMETEK Announces Record Second Quarter 2026 Results and Raises Full Year Guidance Berwyn, Pa., Aug 4, 2026 – AMETEK, Inc. (NYSE: AME) today announced its financial results for the second quarter ended June 30,